GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States... Show more
GT Biopharma, Inc. is a clinical-stage biotechnology company that develops immunotherapy treatments intended to harness the body's immune system to fight cancer. Investors follow GTBP primarily because of its proprietary TriKE platform, a novel approach to engaging natural killer (NK) cells — a type of immune cell — against tumors. Because the company is still in the development stage, its business model and long-term prospects depend heavily on the progress of its clinical pipeline rather than on current revenue.
GT Biopharma, Inc. is headquartered in San Francisco, California, and trades on the Nasdaq Capital Market under the ticker GTBP. The company was incorporated in 1965 and was formerly known as OXIS International, Inc.; it adopted the GT Biopharma name in July 2017, reflecting its focus on translational immunotherapy research.
The company's core technology is the TriKE (Tri-specific Killer Engager) platform. TriKE molecules are engineered proteins that bring together three components: one arm binds to the CD16 receptor on natural killer cells, a second arm binds to a specific target on cancer cells, and a central IL-15 component stimulates NK cell proliferation and activation. In simple terms, the technology is designed to redirect and energize a patient's own NK cells so they can recognize and destroy tumor cells more effectively. The company also works with a related Tetra-specific Killer Engager platform for certain applications.
GT Biopharma's pipeline is its primary asset. Its lead programs include:
GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using the TriKE technology. This academic collaboration is a central part of the company's research foundation. The company is led by Executive Chairman and Chief Executive Officer Michael Breen.
As a development-stage enterprise, GT Biopharma does not yet generate product revenue. Its financial profile is characterized by research and development spending and recurring net losses, which is typical for a company whose value is tied to the outcome of clinical trials. The company maintains a lean operating structure and funds its work through equity offerings and other financing.
GT Biopharma attracts attention primarily for its differentiated approach within the broader immuno-oncology field. While many immunotherapies focus on T cells, GT Biopharma's TriKE platform centers on natural killer cells, an area with substantial scientific interest but fewer clinically validated competitors. The platform's modular design is intended to allow the company to target different cancers by swapping the tumor-binding arm, potentially giving it flexibility to expand into new indications.
The company's expansion from blood cancers into solid tumors and, prospectively, autoimmune diseases represents a long-term growth driver that broadens its potential market. The use of camelid nanobody technology and subcutaneous dosing for newer candidates is also positioned as a potential advantage in terms of patient convenience and manufacturability. Investors monitor clinical data readouts, regulatory milestones, and the company's ability to secure additional funding as key signals of progress.
Investing in GT Biopharma involves substantial, well-documented risks. As a clinical-stage company, it has no approved products and no product revenue, meaning its value is tied almost entirely to the success of its experimental drug candidates. Clinical trials can fail, be delayed, or produce unfavorable safety or efficacy data at any stage, and regulatory approval is never guaranteed.
The company also faces significant financing risk. It has historically relied on equity offerings to fund operations, which can dilute existing shareholders, and it must periodically raise capital to continue its research programs. Its ability to remain listed on Nasdaq has at times been subject to meeting minimum listing requirements, which adds a further layer of uncertainty.
GT Biopharma operates in a highly competitive field, competing against larger, better-capitalized biotechnology and pharmaceutical companies also developing cancer immunotherapies. Its small size, limited staff, and dependence on a single licensed technology platform concentrate its risk. Macroeconomic conditions can also affect the availability and cost of capital for early-stage biotech companies.
For investors seeking to evaluate companies like GT Biopharma alongside thousands of other opportunities, Tickeron's AI Screener is an AI-powered stock and ETF discovery platform. It helps traders and investors identify potential ideas using technical indicators, fundamentals, volatility, trends, AI-generated signals, industry classifications, price patterns, and customizable filters. Users can efficiently screen large universes of stocks and ETFs to surface opportunities that match their own investment strategies. Explore the AI Screener to refine your research process.
GT Biopharma is a small, clinical-stage immuno-oncology company whose story revolves around a single, distinctive technology platform. Its TriKE approach to engaging natural killer cells gives it a differentiated position in cancer immunotherapy, but the company remains in the earliest, highest-risk phase of drug development. For investors, GT Biopharma represents a speculative, research-driven opportunity whose future depends on clinical results, regulatory progress, and continued access to capital.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology